0000950170-24-065229.txt : 20240528 0000950170-24-065229.hdr.sgml : 20240528 20240528161751 ACCESSION NUMBER: 0000950170-24-065229 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240528 DATE AS OF CHANGE: 20240528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 24992099 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 8-K 1 evok-20240522.htm 8-K 8-K
0001403708--12-31false00014037082024-05-222024-05-22

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2024

 

 

EVOKE PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-36075

20-8447886

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

420 Stevens Avenue, Suite 230

 

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 345-1494

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

EVOK

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Mark A. Kowieski to Chief Financial Officer.

 

On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer ("CFO") of Evoke Pharma, Inc. (the "Company") effective May 22, 2024.

 

Mr. Kowieski has previously served as the Company’s Vice President of Finance since June 2022. Before working at the Company, Mr. Kowieski served as Vice President, Finance and Accounting of Evofem Biosciences, a biotechnology company, from May 2015 to May 2022. From December 2012 to May 2015, Mr. Kowieski served as Director of SEC Reporting and Budgets, and Director of Accounting Operations at Vital Therapies, Inc. Prior to this time, Mr. Kowieski served in a variety of financing and accounting roles in technology and life sciences companies with increasing responsibilities. Mr. Kowieski started his career at Arthur Anderson, where he worked from 2000 to 2002. Mr. Kowieski received his B.A. in Business Administration and an M.A. in Accountancy from University of Wisconsin, and he has been a Certified Public Accountant since 2004.

 

There are no arrangements or understandings between Mr. Kowieski and any other person pursuant to which he was selected as an officer, and there are no family relationships between Mr. Kowieski and any of the Company’s directors or executive officers. Mr. Kowieski has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under item 404(a) of Regulation S-K.

 

Mr. Kowieski and the Company are parties to an employment agreement (the “Kowieski Employment Agreement”). The Kowieski Employment Agreement was effective as of June 13, 2022. Mr. Kowieski is eligible to receive an annual base salary of $390,000, with a target annual bonus opportunity of 40% of his base salary. Mr. Kowieski is eligible to participate in the Company’s health, retirement, expense reimbursement and other benefit plans.

 

Pursuant to the Kowieski Employment agreement, if we terminate Mr. Kowieski's employment without cause or Mr. Kowieski resigns for good reason, Mr. Kowieski is entitled to the following payments and benefits: (1) fully earned but unpaid base salary through the date of termination at the rate then in effect, plus all other amounts under any compensation plan or practice to which he is entitled; (2) a lump sum cash payment in an amount equal to his monthly base salary as in effect immediately prior to the date of termination for a period of nine months; (3) to the extent such termination occurs within 12 months following a change in control, a lump sum cash payment in an amount equal to his bonus for the year in which the termination of his employment occurs, prorated for the period of his service during such year; and (4) continued healthcare benefits for a period of nine months. In the event Mr. Kowieski’s termination without cause or resignation for good reason occurs within three months prior to the occurrence of a change in control or within 12 months following a change in control, all of his outstanding unvested stock awards will accelerate and become fully vested on the later of (1) the date of termination or (2) the date of such change in control, and will remain exercisable for a period of twelve (12) months following his termination of employment (or, if later, the date of the change in control).

 

The foregoing summary of the Kowieski Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Kowieski Employment Agreement. A copy of the Kowieski Employment Agreement will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

 

Base Salary and Target Bonus Increase for Matthew J. D’Onofrio

 

In March 22, 2024, the Board approved an increase to the compensation of Matthew J. D’Onofrio, our Chief Executive Officer, increasing his base salary to $615,000 and his target annual bonus to 60% of his annual base salary. The other elements of Mr. D’Onofrio’s compensation remain the same.

 

Approval of Amendment and Restatement of Evoke Pharma, Inc. 2013 Equity Incentive Award Plan

 

The Company held its annual meeting of stockholders (the “Annual Meeting”) solely by means of remote communication through a live webcast on May 22, 2024, at 8:30 a.m., Pacific Time. At the Annual Meeting, the Company's stockholders approved the amendment and restatement of the Company’s 2013 Equity Incentive Award Plan (the “2013 Plan”). The amended and restated 2013 Plan is referred to herein as the “Restated Plan.” The Restated Plan increases the number of shares of common stock authorized for issuance under the 2013 Plan by 4,000,000 shares, to an aggregate of 5,395,301 shares. In addition, the Restated Plan contains an “evergreen provision” that allows for an annual increase in the number of shares available for issuance under the Restated Plan on January 1 of each year during the ten-year term of the Restated Plan, beginning on January 1, 2025. The annual increase in the number of shares is equal to the least of: (a) 6% of the Company’s outstanding capital stock on the last day of the immediately preceding calendar year; and (b) an amount determined by the Company’s board of directors (the “Board”). Notwithstanding the foregoing, the

number of shares of common stock that may be issued or transferred pursuant to incentive stock options under the Restated Plan may not exceed an aggregate of 250,000,000 shares.

 

The Restated Plan authorizes the compensation committee of the Board (the “Compensation Committee”) to grant stock options, restricted stock, restricted stock units, dividend equivalents, stock payment awards and stock appreciation rights. The Restated Plan also authorizes the Compensation Committee to grant performance awards payable in the form of the Company’s common stock or cash. The Restated Plan authorizes the grant of awards to employees and consultants of the Company and to the Company’s non-employee directors. In addition, the sum of any cash compensation, or other compensation, and the value of awards granted to a non-employee director as compensation for services as a non-employee director during any calendar year may not exceed $400,000.

 

The Restated Plan also contains provisions with respect to payment of exercise or purchase prices, vesting and expiration of awards, adjustments and treatment of awards upon certain corporate transactions, including stock splits, recapitalizations and mergers, transferability of awards and tax withholding requirements. The Restated Plan may be amended or terminated by the Board at any time, subject to certain limitations requiring stockholder consent or the consent of the participant. The Restated Plan will expire in February 2034.

 

The terms and conditions of the Restated Plan are described in the section entitled “Proposal 6 - Approval of Amendment and Restatement of 2013 Equity Incentive Award Plan” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 10, 2024. The Company’s directors and executive officers are eligible to participate in the Restated Plan. The foregoing description of the Restated Plan does not purport to be complete and is qualified in its entirety by reference to the complete text of the Restated Plan, which is filed as Exhibit 10.1 to this report and incorporated herein by reference.

 

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On May 22, 2024, the Company's stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 50,000,000 shares to 100,000,000 shares (the “Amendment”). In connection with the approval of the Amendment, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on May 24, 2024.

 

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the Certificate of Amendment, a copy of which are attached hereto as Exhibits 3.1, and incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting solely by means of remote communication through a live webcast on May 22, 2024, at 8:30 a.m., Pacific Time. There were represented at the Annual Meeting, by proxy, 5,694,603 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), out of a total number of 8,477,801 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following three proposals at the Annual Meeting, casting their votes as described below.

The following individuals, who were named as nominees in the Company’s definitive proxy statement relating to the Annual Meeting, were elected by the Company’s stockholders by a plurality of votes cast to serve a three-year term on the Company’s Board of Directors which will expire at the Company’s 2027 annual meeting of stockholders. Information on the vote relating to the director standing for election is set forth below:

 

Proposal 1. – Election of Class II Directors.

Nominee

For

Withheld

Broker Non-Votes

Mr. Cam L. Garner

2,002,022

1,235,636

2,456,945

Mr. Todd C. Brady, M.D., Ph.D.

1,883,425

1,354,233

2,456,945

 

 

 

 

 

Proposal 2. – Ratification of Appointment of BDO USA, P.C.

Proposal 2 was to ratify the appointment of BDO USA, P.C., an independent registered public accounting firm, as the Company’s independent auditors for the year ending December 31, 2024. The proposal was approved.

For

Against

Abstain

4,812,924

852,736

28,943


 

Proposal 3. – Advisory Vote on Executive Compensation.

Proposal 3 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved.

For

Against

Abstain

Broker Non-Votes

1,734,876

1,500,433

2,349

2,456,945

Proposal 4. – Amendment and Restatement of Amended and Restated Certificate of Incorporation.

Proposal 4 was to approve an increase to the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares. The proposal was approved.

For

Against

Abstain

2,932,567

2,758,083

3,950


 

Proposal 5. – Grant the Board Authority to Effect a Reverse Stock Split of the Common Company's Common Stock Within One Year.

Proposal 5 was to grant authority to the Board to effect a reverse stock split of our outstanding common stock by amending our Amended and Restated Certificate of Incorporation within one year and within a range of not less than one-for-two and not more than one-for-twenty, if the board deems it within the Company’s best interests. The proposal was approved.

 

For

Against

Abstain

3,561,718

2,103,718

29,164

 

Proposal 6. – Amendment and Restatement of our 2013 Equity Incentive Award Plan.

Proposal 6 was to approve and increase in the number of shares available for issuance under our 2019 Equity Incentive Award Plan. The proposal was approved.

For

Against

Abstain

Broker Non-Votes

1,720,068

1,512,008

5,582

2,456,945

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

Exhibit No.

Description

3.1*

 

Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company.

 

 

 

10.1

 

Evoke Pharma, Inc. Amended and Restated 2013 Equity Incentive Award Plan (incorporated by reference to Appendix C to the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 10, 2024)

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EVOKE PHARMA, INC.

 

 

 

 

Date:

May 28, 2024

By:

/s/ Matthew J. D'Onofrio

 

 

 

Name: Matthew J. D'Onofrio
Title: Chief Executive Officer and Director

 

 EX-3.1 2 evok-ex3_1.htm EX-3.1 EX-3.1

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

 

OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

 

OF EVOKE PHARMA, INC.

 

Evoke Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:

1. The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Evoke Pharma, Inc. was filed with the Secretary of State of Delaware on January 29, 2007.

2. This Certificate of Amendment hereby amends and restates Article FOURTH of the Corporation’s Amended and Restated Certificate of Incorporation to read in its entirety as follows:

FOURTH: The Corporation is authorized to issue two classes of stock to be designated, respectively, Common Stock, par value $0.0001 per share (“Common Stock”) and Preferred Stock, par value $0.0001 per share (“Preferred Stock”). The total number of shares the Corporation shall have the authority to issue is One Hundred Five Million (105,000,000) shares, One Hundred Million (100,000,000) shares of which shall be Common Stock and Five Million (5,000,000) shares of which shall be Preferred Stock.

(1) Common Stock. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock. The holders of the Common Stock are entitled to one vote for each share held at all meetings of stockholders. There shall be no cumulative voting. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors and subject to any preferential dividend rights of any then outstanding Preferred Stock. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of the Corporation will be entitled to receive ratably all assets of the Corporation available for distribution to stockholders, subject to any preferential rights of any then outstanding Preferred Stock.

(2) Preferred Stock. Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated in the resolution or resolutions providing for the establishment of such series adopted by the Board of Directors of the Corporation as hereinafter provided. Authority is hereby expressly granted to the Board of Directors of the Corporation to issue, from time to time, shares of Preferred Stock in one or more series, and, in connection with the establishment of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the DGCL, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such other powers, designations, preferences and relative, participating, optional and other special rights, and the qualifications, limitations and restrictions thereof, if any, including, without limitation, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated in such resolution or resolutions, all to the fullest extent permitted by the DGCL. Without limiting the generality of the foregoing, the resolution or resolutions providing for the establishment of any series of Preferred Stock may, to the extent permitted by law, provide that such series shall be superior to, rank equally with or be junior to the Preferred Stock of any other series. The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may be different from those of any and all other series at any time outstanding. Except as otherwise expressly provided in the resolution or resolutions providing for the establishment of any series of Preferred Stock, no vote of the holders of shares of Preferred Stock or Common Stock shall be a prerequisite to the issuance of any shares of any series of the Preferred Stock authorized by and complying with the conditions of this Amended and Restated Certificate of Incorporation.

3. This Certificate of Amendment shall become effective as of May 24, 2024 at 5:00 p.m. Eastern time.

4. This Certificate of Amendment was duly adopted in accordance with Section 242 of the DGCL. The Board of Directors of the Corporation duly adopted resolutions setting forth and declaring advisable this Certificate of Amendment and directed that such amendment be considered by the stockholders of the Corporation. An annual meeting of stockholders was duly called upon notice in accordance with Section 222 of the DGCL and held on May 22, 2024, at which meeting the necessary number of shares were voted in favor of such amendment. The stockholders of the Corporation duly adopted this Certificate of Amendment.

 

 

 

IN WITNESS WHEREOF, this Certificate of Amendment of Amended and Restated Certificate of Incorporation has been executed as of this 24th day of May, 2024.

 

 

 

EVOKE PHARMA, INC.

 

 

By: /s/ Matthew J. D’Onofrio

Name: Matthew J. D’Onofrio

Title: Chief Executive Officer

 

 

 

 

 

 

 

|||

 EX-10.1 3 evok-ex10_1.htm EX-10.1 EX-10.1

 

 EX-101.SCH 4 evok-20240522.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Current Fiscal Year End Date Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
May 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Period End Date May 22, 2024
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue, Suite 230
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code 858
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #B"O%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " X@KQ8!NI1O_ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NLTV0%'7"]-.("$Q"<0M 40\DM,Q'Q/MV-QWP6D>G^$ 7N.' M/A#(HK@%1ZR-9@T3,/,S4=25086!-'?AC#WI\26MF]DV MLFZ1QE_1*CYY6HO+Y-?%PV:W%;4LY#(K5IF\W\E"E7=JN7J?7'_X785=9^S> M_F/CBV!=P:^[J+\ 4$L#!!0 ( #B"O%B97)PC$ 8 )PG 3 >&PO M=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$ M[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4 M\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6 M:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+ MTHMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3 M:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ M %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ W MQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYK ME']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6? MR"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^: M/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B" MP#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F M.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1 MN0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/ MPT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,K MD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5; M\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;Z MEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX# M7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1 M/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% M @ .(*\6$-\56E_! 4A$ !@ !X;"]W;W)K/[^[;'I\5']OM@\;&;!-)_(^*N(S'KD#!P2\27+8_,BMY_X84,%8"AC77R2[?Y: MWW=(F&LCDX,Q$"0BW7^SMX,C3@WH&0-Z,* %]_Y&!>4M,VP\5')+E+T:U.Q! ML=7"&N!$:J,R-PI^%6!GQKPT$9!!/^J ]HK M^/4*-JVO=<9"/G(@;S57&^Z,?_C.Z[D_(WR=DJ^#J5?^>]UEO X.-Q^T'A ( MOX3P494 "**"XCYFJSH*W'[)8LT1CF[)T45U)KE2!870(8O)[YPIR*F(0&;6 M^@97:[4\VNIX"%>OY.I]+$@SKH2,4"9G=+\GZJ-[AB7OA*V$3'!"? M6%++U:#SY?GACLP^!2^/P069/DTN$;A!"3?X"-P$/*<@G-,TXF_D@>_J\' E MUW4]W^WTW0&"=55B77T$ZR[A:B72%?D%[,V:3&22L;06#M=KRG[/K6JI^Q&R M>Q%S\I0G"ZYJZR>F)7$/17N:UO[+C<7,8L9>2&LW"-\57=PL,+_'N^,BMG2FY$ M&M9[M:$%!1A:U3 \O,Z_1YM);: $_B&R\X\*KGA%&Q[IJF5X>*TOPAC "'X> M!16HGXC(H(L59Z]J&AY>ZS]+V_MG:YFB11 7Z?C=EN=?82W6J_J%AQ?XKTH8 MPU/;(9(\/90674OU_SH%K3H%Q8L\/$LB%,:VKT=(>B587#O9XBJ-/%6;H'@A MGRG>"L$]')ZZ_3@+$R4,WL_+97W\&O0:R4[F?[R0_X=LJG4.9(V N&PC8-4: M*%['7X6!=B^7Q*,_+GXBT%9DZ,I.H#%*_91Y>1N[=P MS=(5/SL$-P@]!?/;X- 4O#M><0<;9"^#WI93FN+#OX>7?*.-_ %!+ P04 " X@KQ8GZ ; M\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2) M8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@ M7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY M!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"P MU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1 M%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.] MFZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PEY7 M>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[ MJ,NXZBQ_AOMHD\%G'!QR>(W?#$T%^@2O&+(=/EB>N$_NG_A.\SQ-LPRK MZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#Q MNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q M_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_5U/\!%!+ P04 M " X@KQ8EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_ MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@ M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 ( #B"O%@ZJJ+G0 $ #P" / >&PO=V]R:V)O;VLN M>&ULC5%=:\,P#/PKQC]@20SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;B(S5'WC3B?PT9>H1-N6'$2&% MGN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D0XMAU]&(B^S"1I_#6(<0Y_$_ M,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB[H-5CX$E)+4* Y7L=D[E],H. MKEGD7F08YRB#N+*#\%&MA1H#V#:;7-Y-;2>C@W(-@[^&5 MC!W-CQ]W]P-02P,$% @ .(*\6"0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C M,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI M160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=% MKLWC":[?#'!X=/X!4$L#!!0 ( #B"O%AED'F2&0$ ,\# 3 6T-O M;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^ MDV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT M(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W" MS&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE M8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F M"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 M ( #B"O%A#?%5I?P0 %(1 8 " @0\( !X;"]W;W)K M&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " X@KQ899!YDAD! #/ P $P @ ';$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" E% ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports evok-20240522.htm evok-20240522.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "evok-20240522.htm": { "nsprefix": "evok", "nsuri": "http://www.evokepharma.com/20240522", "dts": { "inline": { "local": [ "evok-20240522.htm" ] }, "schema": { "local": [ "evok-20240522.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_bbd0c36e-0e6a-4cbd-89d5-68ce77417c75", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "evok-20240522.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bbd0c36e-0e6a-4cbd-89d5-68ce77417c75", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "evok-20240522.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.evokepharma.com/20240522/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-065229-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-065229-xbrl.zip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evok-20240522_htm.xml IDEA: XBRL DOCUMENT 0001403708 2024-05-22 2024-05-22 0001403708 --12-31 false 8-K 2024-05-22 EVOKE PHARMA, INC. DE 001-36075 20-8447886 420 Stevens Avenue, Suite 230 Solana Beach CA 92075 858 345-1494 false false false false Common Stock, par value $0.0001 per share EVOK NASDAQ false